drugset / Trial / NCT03553433

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

NCT03553433

Phase 4 Unknown 90 enrolled University of Zurich
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis

Timeline

Start
2018-06
Primary completion
2019-12
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg

Indications